Guía de práctica clínica para el diagnóstico y tratamiento de la infección por helicobacter pylori en adultos: actualización 2025
DOI:
https://doi.org/10.22516/25007440.1458Palabras clave:
Helicobacter pylori, Diagnóstico, Terapia, Guía de práctica clínicaResumen
Introducción: en 2015, la Asociación Colombiana de Gastroenterología (ACG) publicó la guía de práctica clínica (GPC) para el diagnóstico y tratamiento de la infección por Helicobacter pylori en adultos. En 2025, la Asociación realizó el proceso de actualización de esta guía de acuerdo con la necesidad de actualización de las estrategias diagnósticas y terapéuticas, adaptadas a la realidad microbiológica local y a las características clínicas de la población.
Materiales y métodos: el comité de guías de la ACG con el acompañamiento de epidemiólogos realizó la actualización con base en una revisión sistemática de recomendaciones de práctica y metaanálisis siguiendo las directrices de la metodología GRADE. En esta versión corta de la GPC-actualización 2025 se presenta un breve resumen de la evidencia que apoya las recomendaciones. El detalle del proceso de actualización puede consultarse en la versión completa disponible en www.gastrocol.com.
Resultados: la actualización de 2025 presenta recomendaciones sobre indicaciones de tratamiento para curar el H. pylori y prevenir otras patologías, métodos diagnósticos invasivos y no invasivos, alternativas de tratamiento en las diferentes líneas y consideraciones particulares como zonas de alta resistencia, alergia a la penicilina y poblaciones especiales.
Conclusión: un adecuado diagnóstico y tratamiento de la infección por H. pylori es esencial dado su rol como factor de riesgo en condiciones como gastritis crónica, úlceras pépticas, linfoma MALT gástrico y adenocarcinoma del estómago.
Descargas
Referencias bibliográficas
Chen YC, Malfertheiner P, Yu HT, Kuo CL, Chang YY, Meng FT, et al. Global Prevalence of Helicobacter pylori Infection and Incidence of Gastric Cancer Between 1980 and 2022. Gastroenterology. 2024;166(4):605-19. https://doi.org/10.1053/j.gastro.2023.12.022
Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022;71(9):1724-62. https://doi.org/10.1136/gutjnl-2022-327745
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1-441.
Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, et al. Global Cancer Observatory: Cancer Today (version 1.1) [Internet]. Lyon, France: International Agency for Research on Cancer; 2024 [consultado el 30 de septiembre de 2025]. Disponible en: https://gco.iarc.who.int/today
Arévalo A, Otero WA, Trespalacios AA. Helicobacter pylori: resistencia múltiple en pacientes de Bogotá, Colombia. Biomed. 2019;39(Sp. 1):125-34. https://doi.org/10.7705/biomedica.v39i3.4437
Otero R. W, Riquelme A, Remes-Troche JM, Laudanno O, Piscoya A, Marulanda H, et al. Actualización en el tratamiento de Helicobacter pylori: revisión del LATAMGCHMSG. Rev Gastroenterol Peru. 2024;44(4):359-73. https://doi.org/10.47892/rgp.2024.444.1797
Otero W, Trespalacio AA, Otero L, Vallejo MT, Torres M, Pardo R, et al. Guía de práctica clínica para el diagnóstico y tratamiento de la infección por Helicobacter pylori en adultos. Rev Col Gastroenterol. 2015;30(Supl 1):17-33.
Schünemann H, Brożek J, Guyatt G, Oxman A. GRADE handbook for grading quality of evidence and strength of recommendations using the GRADE approach. The GRADE Working Group; 2013. Disponible en: guidelinedevelopment.org/handbook
Patel A, Laine L, Moayyedi P, Wu J. AGA Clinical Practice Update on Integrating Potassium-Competitive Acid Blockers Into Clinical Practice: Expert Review. Gastroenterology. 2024;167(6):1228-38. https://doi.org/10.1053/j.gastro.2024.06.038
Sun M, Liu E, Yang L, Cao H, Han M. A scoping review of worldwide guidelines for diagnosis and treatment of Helicobacter pylori infection. Syst Rev. 2025;14(1):107. https://doi.org/10.1186/s13643-025-02816-0
Ford AC, Yuan Y, Park JY, Forman D, Moayyedi P. Eradication Therapy to Prevent Gastric Cancer in Helicobacter pylori-Positive Individuals: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies. Gastroenterology. 2025;169(2):261-76. https://doi.org/10.1053/j.gastro.2024.12.033
Godbole G, Mégraud F, Bessède E. Review: Diagnosis of Helicobacter pylori infection. Helicobacter. 2020;25(S1):e12735. https://doi.org/10.1111/hel.12735
Cardos AI, Maghiar A, Zaha DC, Pop O, Fritea L, Miere Groza F, et al. Evolution of Diagnostic Methods for Helicobacter pylori Infections: From Traditional Tests to High Technology, Advanced Sensitivity and Discrimination Tools. Diagnostics (Basel). 2022;12(2):508. https://doi.org/10.3390/diagnostics12020508
Ansari S, Yamaoka Y. Helicobacter pylori Infection, Its Laboratory Diagnosis, and Antimicrobial Resistance: a Perspective of Clinical Relevance. Clin Microbiol Rev. 2022;35(3):e00258-21. https://doi.org/10.1128/cmr.00258-21
Lemos FFB, Castro CTD, Silva Luz M, Rocha GR, Correa Santos GL, De Oliveira Silva LG, et al. Urea breath test for Helicobacter pylori infection in adult dyspeptic patients: A meta-analysis of diagnostic test accuracy. World J Gastroenterol. 2024;30(6):579-98. https://doi.org/10.3748/wjg.v30.i6.579
Liou JM, Chen PY, Luo JC, Lee JY, Chen CC, Fang YJ, et al. Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection. Gastroenterology. 2018;155(4):1109-19. https://doi.org/10.1053/j.gastro.2018.06.047
Chey WD, Howden CW, Moss SF, Morgan DR, Greer KB, Grover S, et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2024;119(9):1730-53. https://doi.org/10.14309/ajg.0000000000002968
Gingold‐Belfer R, Niv Y, Schmilovitz‐Weiss H, Levi Z, Boltin D. Susceptibility‐guided versus empirical treatment for Helicobacter pylori infection: A systematic review and meta‐analysis. J Gastroenterol Hepatol. 2021;36(10):2649-58. https://doi.org/10.1111/jgh.15575
Bujanda L, Nyssen OP, Ramos J, Bordin DS, Tepes B, Perez-Aisa A, et al. Effectiveness of Helicobacter pylori Treatments According to Antibiotic Resistance. Am J Gastroenterol. 2024;119(4):646-54. https://doi.org/10.14309/ajg.0000000000002600
Dong F, Ji D, Huang R, Zhang F, Huang Y, Xiang P, et al. Multiple Genetic Analysis System-Based Antibiotic Susceptibility Testing in Helicobacter pylori and High Eradication Rate With Phenotypic Resistance-Guided Quadruple Therapy. Medicine (Baltimore). 2015;94(47):e2056. https://doi.org/10.1097/MD.0000000000002056
Jones NL, Koletzko S, Goodman K, Bontems P, Cadranel S, Casswall T, et al. Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016). J Pediatr Gastroenterol Nutr. 2017;64(6):991-1003. https://doi.org/10.1097/MPG.0000000000001594
Vasapolli R, Ailloud F, Spießberger B, Malfertheiner P, Suerbaum S, Schulz C. Real‐Time Assessment of H. pylori Infection to Guide Molecular Antibiotic Resistance Testing: A Combined Endoscopy‐Gastric Juice Analysis Approach. Aliment Pharmacol Ther. 2025;61(3):465-71. https://doi.org/10.1111/apt.18378
Egli K, Wagner K, Keller PM, Risch L, Risch M, Bodmer T. Comparison of the Diagnostic Performance of qPCR, Sanger Sequencing, and Whole-Genome Sequencing in Determining Clarithromycin and Levofloxacin Resistance in Helicobacter pylori. Front Cell Infect Microbiol. 2020;10:596371. https://doi.org/10.3389/fcimb.2020.596371
Zhou Y, Zhong Z, Hu S, Wang J, Deng Y, Li X, et al. A Survey of Helicobacter pylori Antibiotic-Resistant Genotypes and Strain Lineages by Whole-Genome Sequencing in China. Antimicrob Agents Chemother. 2022;66(6):e02188-21. https://doi.org/10.1128/aac.02188-21
Aumpan N, Issariyakulkarn N, Mahachai V, Graham D, Yamaoka Y, Vilaichone RK. Management of Helicobacter pylori treatment failures: A large population-based study (HP treatment failures trial). PLoS One. 2023;18(11):e0294403. https://doi.org/10.1371/journal.pone.0294403
Chang YW, Shin GY, Kim JW, Moon JC, Chang EJ, Oh CH, et al. Cost-Effectiveness of Empirical Bismuth-Based Quadruple Therapy and Tailored Therapy After Clarithromycin Resistance Tests for Helicobacter pylori Eradication. Dig Dis Sci. 2022;67(4):1222-30. https://doi.org/10.1007/s10620-021-06938-y
Nan X, Zhao H, Guo L, Zheng R, Wang X, Wang Y, et al. Seven‐day versus 14‐day tegoprazan and tetracycline‐containing quadruple therapy for first‐line eradication of Helicobacter pylori infection: a randomized, open‐label, noninferiority trial. Helicobacter. 2025;30(2):e70036. https://doi.org/10.1111/hel.70036
Jung YS, Kim S, Kim H, Noh SJ, Park JH, Park CH. 7‐day versus 14‐day tegoprazan‐based triple therapy to treat HELICOBACTER PYLORI infection: Real‐world evidence. J Gastroenterol Hepatol. 2022;37(10):1911-8. https://doi.org/10.1111/jgh.15939
Liou JM, Malfertheiner P, Hong TC, Cheng HC, Sugano K, Shah S, et al. Screening and eradication of Helicobacter pylori f or gastric cancer prevention: Taipei Global Consensus II. Gut. 2025;74(11):1767-1791. https://doi.org/10.1136/gutjnl-2025-336027
Nyssen OP, Bordin D, Tepes B, Pérez-Aisa Á, Vaira D, Caldas M, et al. European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut. 2021;70(1):40-54. https://doi.org/10.1136/gutjnl-2020-321372
Qian HS, Li WJ, Dang YN, Li LR, Xu XB, Yuan L, et al. Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy. Am J Gastroenterol. 2023;118(4):627-34. https://doi.org/10.14309/ajg.0000000000002086
Ouyang M, Zou S, Cheng Q, Shi X, Sun M. Comparative Efficacy and Safety of Potassium‐Competitive Acid Blockers and Proton Pump Inhibitors for First‐Line Helicobacter pylori Eradication Therapy: A Systematic Review and Network Meta‐Analysis. Helicobacter. 2024;29(6):e13150. https://doi.org/10.1111/hel.13150
Han Z, Li Y, Kong Q, Liu J, Wang J, Wan M, et al. Efficacy of bismuth for antibiotic‐resistant Helicobacter pylori strains eradication: A systematic review and meta‐analysis. Helicobacter. 2022;27(6):e12930. https://doi.org/10.1111/hel.12930
Reum Choe A, Tae CH, Choi M, Shim K, Jung H. Systematic Review and Meta‐Analysis: Bismuth Enhances the Efficacy for Eradication of Helicobacter pylori. Helicobacter. 2024;29(5):e13141. https://doi.org/10.1111/hel.13141
Wang J, Cao Y, He W, Li X. Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of Helicobacter pylori. Medicine (Baltimore). 2021;100(51):e28323. https://doi.org/10.1097/MD.0000000000028323
Urrego JA, Otero W, Cedrón H, Marulanda H, Piscoya A, Frías-Ordoñez JS, et al. [Potassium-competitive acid blockers: state of the art]. Rev Gastroenterol Peru Organo Of Soc Gastroenterol Peru. 2025;45(1):38-55. https://doi.org/10.47892/rgp.2025.451.1873
Shah SC, Iyer PG, Moss SF. AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review. Gastroenterology. 2021;160(5):1831-41. https://doi.org/10.1053/j.gastro.2020.11.059
Taufiqqurrachman I, Syam AF, Maulahela H, Abdullah M, Miftahussurur M, Yamaoka Y. Comparative Efficacy and Safety of Potassium-Competitive Acid Blocker- and Proton Pump Inhibitor-Based Bismuth Quadruple Therapy for Helicobacter pylori Eradication: A Network Meta-Analysis. Gastro Hep Adv. 2025;4(9):100705. https://doi.org/10.1016/j.gastha.2025.100705
Liu YH, Zhang J, Li DH, Zhang YP, Li J, Guo QQ, et al. The impact of probiotics on Helicobacter pylori eradication with bismuth quadruple therapy: A systematic review and meta-analysis. Int J Antimicrob Agents. 2025;66(6):107600. https://doi.org/10.1016/j.ijantimicag.2025.107600
Jaramillo-Trujillo G, Otero-Regino WA, Estrada-Orozco KP. Efectividad y seguridad del uso de probióticos como adyuvantes en la erradicación de Helicobacter pylori. Revisión sistemática y metaanálisis. Rev Fac Med. 2022;71(2):e98018. https://doi.org/10.15446/revfacmed.v71n2.98018
Gisbert JP. Optimization Strategies Aimed to Increase the Efficacy of Helicobacter pylori Eradication Therapies with Quinolones. Molecules. 2020;25(21):5084. https://doi.org/10.3390/molecules25215084
Laudano O, Riquelme A, Ahumaran G, Thome M, Gollo P, Gonzalez P. efficacy and safety of a tailored helicobacter pylori eradicacion therapy based on high-dose amoxicillin in obese patients. a post-hoc analysis of two multicenter prospective cohort studies. Gastroenterology. 2023;164(6):S-47. https://doi.org/10.1016/S0016-5085(23)01069-7
Barreda-Costa CS, Piccini-Larco JR, Chu-Revollar LD, Salazar-Muente F, Barriga-Briceño JA, Herrera-Alzamora MA. Tratamiento cuádruple con doxiciclina, furazolidona, bismuto e inhibidor de bomba de protones sigue siendo efectivo frente al Helicobacter pylori en nuestra población. Rev Gastroenterol Peru. 2023;43(2):e1458. https://doi.org/10.47892/rgp.2023.432.1458
Gutiérrez O, Otero W, Cardona H, Quintero F, Orozco C, Sánchez L. Terapia cuádruple con furazolidona como tratamiento de rescate para la infección por Helicobacter pylori. Rev Col Gastroenterol. 2003;18(4):222-227.
Borraccino AV, Celiberto F, Pricci M, Girardi B, Iannone A, Rendina M, et al. Rifabutin as salvage therapy for Helicobacter pylori eradication: Cornerstones and novelties. World J Gastroenterol. 2022;28(45):6356-62. https://doi.org/10.3748/wjg.v28.i45.6356
Nyssen OP, Vaira D, Saracino IM, Fiorini G, Caldas M, Bujanda L, et al. Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg). J Clin Med. 2022;11(6):1658. https://doi.org/10.3390/jcm11061658
Valladales-Restrepo LF, Correa-Sánchez Y, Aristizábal-Carmona BS, Machado-Alba JE. Treatment regimens used in the management of Helicobacter pylori in Colombia. Braz J Infect Dis. 2022;26(1):102331. https://doi.org/10.1016/j.bjid.2022.102331
Kotilea K, Mekhael J, Salame A, Mahler T, Miendje‐Deyi VY, Cadranel S, et al. Eradication rate of Helicobacter Pylori infection is directly influenced by adherence to therapy in children. Helicobacter. 2017;22(4):e12383. https://doi.org/10.1111/hel.12383
Eto H, Suzuki S, Kusano C, Ikehara H, Ichijima R, Ito H, et al. Impact of body size on first‐line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy. Helicobacter. 2021;26(2):e12788. https://doi.org/10.1111/hel.12788
Huang Y, Qiu S, Guo Y, Chen J, Li M, Ding Z, et al. Optimization of Minocycline‐Containing Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Real‐World Evidence Study. Helicobacter. 2024;29(5):e13138. https://doi.org/10.1111/hel.13138
Zhuge L, Wang Y, Wu S, Zhao R, Li Z, Xie Y. Furazolidone treatment for Helicobacter Pylori infection: A systematic review and meta‐analysis. Helicobacter. 2018;23(2):e12468. https://doi.org/10.1111/hel.12468
Xie J, Peng J, Wu S, Yang K, Liu D, Shen L, et al. Efficacy and safety of tetracycline vs. amoxicillin in furazolidone-based rescue therapy for Helicobacter pylori: a real-world analysis. Ann Med. 2025;57(1):2464938. https://doi.org/10.1080/07853890.2025.2464938
Gao W, Zhu M, Yin Y, Zhang X, Wang L. Efficacy and safety of minocycline quadruple therapy for Helicobacter pylori eradication: A meta‐analysis of RCTS. Helicobacter. 2023;28(6):e13022. https://doi.org/10.1111/hel.13022
Zhao J, Zou Y, Li K, Huang X, Niu C, Wang Z, et al. Doxycycline and minocycline in Helicobacter pylori treatment: A systematic review and meta‐analysis. Helicobacter. 2021;26(5):e12839. https://doi.org/10.1111/hel.12839
Niv Y. Doxycycline in Eradication Therapy of Helicobacter pylori - A Systematic Review and Meta-Analysis. Digestion. 2016;93(2):167-73. https://doi.org/10.1159/000443683
Morino Y, Sugimoto M, Nagata N, Niikiura R, Iwata E, Hamada M, et al. Influence of Cytochrome P450 2C19 Genotype on Helicobacter pylori Proton Pump Inhibitor-Amoxicillin-Clarithromycin Eradication Therapy: A Meta-Analysis. Front Pharmacol. 2021;12:759249. https://doi.org/10.3389/fphar.2021.759249
Gao W, Liu J, Wang X, Li J, Zhang X, Ye H, et al. Simplified Helicobacter pylori therapy for patients with penicillin allergy: a randomised controlled trial of vonoprazan-tetracycline dual therapy. Gut. 2024;73(9):1414-20. https://doi.org/10.1136/gutjnl-2024-332640
Liu M, Wang Y, Du B. Update on the association between Helicobacter pylori infection and asthma in terms of microbiota and immunity. Allergy Asthma Clin Immunol. 2024;20(1):4. https://doi.org/10.1186/s13223-024-00870-2
Zamani M, Alizadeh‐Tabari S, Hasanpour AH, Eusebi LH, Ford AC. Systematic review with meta‐analysis: association of Helicobacter pylori infection with gastro‐oesophageal reflux and its complications. Aliment Pharmacol Ther. 2021;54(8):988-98. https://doi.org/10.1111/apt.16585
Erőss B, Farkas N, Vincze Á, Tinusz B, Szapáry L, Garami A, et al. Helicobacter pylori infection reduces the risk of Barrett’s esophagus: A meta‐analysis and systematic review. Helicobacter. 2018;23(4):e12504. https://doi.org/10.1111/hel.12504
Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G. Relationship Between Helicobacter pylori Infection and Esophageal Neoplasia: A Meta-analysis. Clin Gastroenterol Hepatol. 2007;5(12):1413-1417.e2. https://doi.org/10.1016/j.cgh.2007.08.010
Bae S, Kim JS, Lee MW, Kim GH, Kim YI, Jung WT, et al. The Cost-Effectiveness of Adding Helicobacter Pylori Screening to the National Gastric Cancer Screening Program in Korea: Protocol for a Cost-Effectiveness Modeling Study. JMIR Res Protoc. 2025;14:e72228. https://doi.org/10.2196/72228
Shah SC, Wang AY, Wallace MB, Hwang JH. AGA Clinical Practice Update on Screening and Surveillance in Individuals at Increased Risk for Gastric Cancer in the United States: Expert Review. Gastroenterology. 2025;168(2):405-416.e1. https://doi.org/10.1053/j.gastro.2024.11.001
Yoo HW, Hong SJ, Kim SH. Helicobacter pylori Treatment and Gastric Cancer Risk After Endoscopic Resection of Dysplasia: A Nationwide Cohort Study. Gastroenterology. 2024;166(2):313-322.e3. https://doi.org/10.1053/j.gastro.2023.10.013
Ono A, Tanaka S, Sawada N, Goto A, Tsugane S, Muraki I, et al. Helicobacter pylori eradication and gastric cancer prevention in a pooled analysis of large-scale cohort studies in Japan. Sci Rep. 2025;15(1):21307. https://doi.org/10.1038/s41598-025-00713-z
Rocha Soares Menegat BL, Rocha Soares Menegat AL, Tadeu Freitas Uchôa Matheus G, Ribeiro MG, Braz L, Ayoub Silva L, et al. Effect of helicobacter pylori eradication on prognosis after gastrectomy for gastric cancer: A systematic review and meta-analysis. J Clin Oncol. 2025;43(16_suppl):e16104. https://doi.org/10.1200/JCO.2025.43.16_suppl.e16104
Lemos FFB, Castro CTD, Calmon MS, Silva Luz M, Pinheiro SLR, Faria Souza Mendes Dos Santos C, et al. Effectiveness of Helicobacter pylori eradication in the treatment of early-stage gastric mucosa-associated lymphoid tissue lymphoma: An up-to-date meta-analysis. World J Gastroenterol. 2023;29(14):2202-21. https://doi.org/10.3748/wjg.v29.i14.2202
Laoruangroj C, Habermann TM, Wang Y, King RL, Lester SC, Thompson CA, et al. Should All Patients With Stage IE Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Receive Antibiotic Eradication Therapy for Helicobacter pylori ? JCO Oncol Pract. 2024;20(8):1103-8. https://doi.org/10.1200/OP.23.00624
Nakamura S, Hojo M. Diagnosis and Treatment for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. J Clin Med. 2022;12(1):120. https://doi.org/10.3390/jcm12010120
Ford AC, Forman D, Bailey AG, Goodman KJ, Axon AT, Moayyedi P. Eradication therapy for Helicobacter pylori in non ulcer dyspepsia: systematic review and meta-analysis of randomized controlled trials. BMJ. 2020;371:m3103. https://doi.org/10.1136/bmj.m3103
Pineda LF, Rosas MC, Amaya M, Rodriguez A, Luque A, Agudelo F, et al. Guía de Práctica Clínica para el diagnóstico y tratamiento de la dispepsia en adultos. Rev Col Gastroenterol 2015;30(Suppl. 1):9-16.
Gómez M, Riveros J, Ruiz O, Concha A, Ángel D, Torres M, et al. Guía práctica para la prevención, Diagnóstico y tratamiento del cáncer gástrico temprano. Rev Col Gastroenterol 2015; 30(Suppl. 1):34- 42.
Oliveros-Wilches R, Grillo-Ardila CF, Vallejo-Ortega M, Gil-Parada F, Cardona-Tobón M, Páramo-Hernández D, et al. Guía de práctica clínica para la prevención primaria y secundaria y diagnóstico temprano de cáncer gástrico. Rev colomb cancerol. 2022;26(1):39-96. https://doi.org/10.35509/01239015.754
Ford AC, Gurusamy KS, Delaney B, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people. Cochrane Database Syst Rev. 2016;4(4):CD003840. https://doi.org/10.1002/14651858.CD003840.pub5
Vakil N. Peptic Ulcer Disease: A Review. JAMA. 2024;332(21):1832-1842. https://doi.org/10.1001/jama.2024.19094
Gisbert JP, Khorrami S, Carballo F, Calvet X, Gené E, Dominguez-Muñoz JE. H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database Syst Rev. 2004;(2):CD004062. https://doi.org/10.1002/14651858.CD004062.pub2
Lanza FL, Chan FK, Quigley EM; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728-38. https://doi.org/10.1038/ajg.2009.115
Chen MJ, Tseng HM, Huang YL, Hsu WN, Yeh KW, Wu TL, et al. Long-term outcome and short-term survival of patients with systemic lupus erythematosus after bacteraemia episodes: 6-yr follow-up. Rheumatology. 2008;47(9):1352-7. https://doi.org/10.1093/rheumatology/ken196
Wenzhen Y, Yumin L, Kehu Y, Bin M, Quanlin G, Donghai W, et al. Iron deficiency anemia in Helicobacter pylori infection: meta-analysis of randomized controlled trials. Scand J Gastroenterol. 2010;45(6):665-76. https://doi.org/10.3109/00365521003663670
Zhu F, Zhang X, Li P, Zhu Y. Effect of Helicobacter pylori eradication on gastric precancerous lesions: A systematic review and meta‐analysis. Helicobacter. 2023;28(6):e13013. https://doi.org/10.1111/hel.13013
Liang Y, Yang Y, Nong R, Huang H, Chen X, Deng Y, et al. Do atrophic gastritis and intestinal metaplasia reverse after Helicobacter pylori eradication? Helicobacter. 2024;29(1):e13042. https://doi.org/10.1111/hel.13042
Benites-Goñi H, Cabrera-Hinojosa D, Latorre G, Hernandez AV, Uchima H, Riquelme A. OLGA and OLGIM staging systems on the risk assessment of gastric cancer: a systematic review and meta analysis of prospective cohorts. Ther Adv Gastroenterol. 2025;18:17562848251325461. https://doi.org/10.1177/17562848251325461
Sitkin S, Lazebnik L, Avalueva E, Kononova S, Vakhitov T. Gastrointestinal microbiome and Helicobacter pylori: Eradicate, leave it as it is, or take a personalized benefit-risk approach? World J Gastroenterol. 2022;28(7):766-74. https://doi.org/10.3748/wjg.v28.i7.766
Shah SC, Camargo MC, Lamm M, Bustamante R, Roumie CL, Wilson O, et al. Impact of Helicobacter pylori Infection and Treatment on Colorectal Cancer in a Large, Nationwide Cohort. J Clin Oncol. 2024;42(16):1881-9. https://doi.org/10.1200/JCO.23.00703
Han B, Kim HJ, Yhim HY, Oh D, Bae SH, Shin HJ, et al. Sequential eradication of Helicobacter pylori as a treatment for immune thrombocytopenia in patients with moderate thrombocytopenia: a multicenter prospective randomized phase 3 study. Ann Hematol. 2022;101(7):1435-45. https://doi.org/10.1007/s00277-022-04782-2
Lee A, Hong J, Chung H, Koh Y, Cho SJ, Byun JM, et al. Helicobacter pylori eradication affects platelet count recovery in immune thrombocytopenia. Sci Rep. 2020;10(1):9370. https://doi.org/10.1038/s41598-020-66460-5
Gutiérrez‐Ramírez L, Garcia‐Dionisio SL, Feo‐Ortega S, González‐Cervera J, Tejera‐Muñoz A, Lucendo AJ, et al. The Association Between HELICOBACTER PYLORI Infection and Eosinophilic Esophagitis: Systematic Review and Meta‐Analysis. Helicobacter. 2025;30(2):e70038. https://doi.org/10.1111/hel.70038
Tang Y, Yang Y, Lv Z. Adverse pregnancy outcomes and Helicobacter pylori infection: A meta-analysis. Int J Clin Pract. 2021;75(10):e14588. https://doi.org/10.1111/ijcp.14588
Zhan Y, Si M, Li M, Jiang Y. The risk of Helicobacter pylori infection for adverse pregnancy outcomes: A systematic review and meta‐analysis. Helicobacter. 2019;24(2):e12562. https://doi.org/10.1111/hel.12562
Nguyen CT, Davis KA, Nisly SA, Li J. Treatment of Helicobacter pylori in Special Patient Populations. Pharmacother J Hum Pharmacol Drug Ther. 2019;39(10):1012-22. https://doi.org/10.1002/phar.2318
Kothari S, Afshar Y, Friedman LS, Ahn J. AGA Clinical Practice Update on Pregnancy-Related Gastrointestinal and Liver Disease: Expert Review. Gastroenterology. 2024;167(5):1033-45. https://doi.org/10.1053/j.gastro.2024.06.014
ACOG Committee Opinion No. 776: Immune Modulating Therapies in Pregnancy and Lactation. Obstet Gynecol. 2019;133(4):e287-95. https://doi.org/10.1097/AOG.0000000000003176
Gomez Cifuentes JD, Sparkman J, Graham DY. Management of upper gastrointestinal symptoms in patients with autoimmune gastritis. Curr Opin Gastroenterol. 2022;38(6):600-6. https://doi.org/10.1097/MOG.0000000000000878
Dilaghi E, Mosciatti L, Dottori L, Ligato I, Esposito G, Pilozzi E, et al. Therapeutic regimens against Helicobacter pylori infection without proton pump inhibitors in patients with corpus atrophic gastritis: a real-life single-centre longitudinal observational study. Ther Adv Gastroenterol. 2025;18:17562848241308035. https://doi.org/10.1177/17562848241308035
Evans JA, Muthusamy VR, Acosta RD, Bruining DH, Chandrasekhara V, Chathadi KV, et al. The role of endoscopy in the bariatric surgery patient. Gastrointest Endosc. 2015;81(5):1063-72. https://doi.org/10.1016/j.gie.2014.09.044
Zhao J, Yuan L, Yu X, Shao Q, Ma J, Yu M, et al. Whole family—based Helicobacter pylori eradication is a superior strategy to single‐infected patient treatment approach: A systematic review and meta‐analysis. Helicobacter. 2021;26(3):e12793. https://doi.org/10.1111/hel.12793
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2025 Revista colombiana de Gastroenterología
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
Los autores/as ceden sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación en esta revista.
Los contenidos están protegidos bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.
